TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma
Open accessAbstract
Key Points: TIGIT expression is upregulated on CD8+ T cells during MM progression and is associated with impaired effector functions. TIGIT deficiency or blockade protects mice against MM and improves effector functions of myeloma patient CD8+ T cells.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Guillerey et al. observed that in both mice and humans, MM progression was associated with high levels of TIGIT expression on CD8+ T cells.
“Guillerey et al., conducted a study in this field (investigating the therapeutic potential of TIGIT blockade to suppress immune responses against MM) and observed that in both mice and humans, MM progression was associated with high levels of TIGIT expression on CD8+ T cells.”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [212]
Results from Guillerey et al. support the development of TIGIT blocking strategies for the treatment of MM patients.
“They also stated that the results obtained from this study support the development of TIGIT blocking strategies for the treatment of MM patients [212].”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [212]
Blocking TIGIT with monoclonal antibodies leads to better function of CD8 T cells of MM patients and suppresses MM growth.
“They finally concluded that blocking TIGIT with the help of monoclonal antibodies leads to better function of CD8 T cells of MM patients and suppresses MM growth.”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [212]
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity
Yano, H., Andrews, L. P., Workman, C. J., & Vignali, D. A. A. (2019) · Immunology · doi:10.1111/imm.13067 · Cited by 116 · see citing works
Alemohammad, H., Najafzadeh, B., Asadzadeh, Z., Baghbanzadeh, A., Ghorbaninezhad, F., Najafzadeh, A., Safarpour, H., Bernardini, R., Brunetti, O., Sonnessa, M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112516 · Cited by 92 · see citing works
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Liu, Z., Xu, X., Liu, H., Zhao, X., Yang, C., & Fu, R. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-023-00456-5 · Cited by 40 · see citing works
Kamrani, S., Naseramini, R., Khani, P., Razavi, Z. S., Afkhami, H., Atashzar, M. R., Nasri, F., Alavimanesh, S., Saeidi, F., & Ronaghi, H. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03741-x · Cited by 27 · see citing works
- Authors
- Guillerey, C., Harjunpää, H., Carrié, N., Kassem, S., Teo, T., Miles, K., Krumeich, S., Weulersse, M., Cuisinier, M., Stannard, K., Yu, Y., Minnie, S. A., Hill, G. R., Dougall, W. C., Avet-Loiseau, H., Teng, M. W. L., Nakamura, K., Martinet, L., & Smyth, M. J.
- Affiliations
- The University of Queensland (AU)
- Inserm (FR)
- QIMR Berghofer Medical Research Institute (AU)
- Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute,
- Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France;
- Corresponding author
- Guillerey, Camille
- Harjunpää, Heidi
- Martinet, Ludovic
- Smyth, Mark J.
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2018-10-18
- Volume
- 132
- Issue
- 16
- Pages
- 1689-1694
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2879746793
- Cited by
- 300
- References
- 2
- Citations by year
- 2026: 13 · 2025: 29 · 2024: 37 · 2023: 43 · 2022: 49 · 2021: 52 · 2020: 42 · 2019: 27 · 2018: 8
- FWCI
- 23.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Bristol-Myers Squibb
- QIMR Berghofer Medical Research Institute
- Cancer Australia (1122183)
- University of Queensland
- Fondation ARC pour la Recherche sur le Cancer
- Medical Research Council
- National Health and Medical Research Council (1071822, 1132519, 1098960, 1107797, 1107417, 1078671)
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- TIGIT, immune checkpoint blockade, multiple myeloma, CD8+ T cells, T cell immunity, tumor immunosuppression
- MeSH terms
- Animals, Antibodies, Monoclonal, Cells, Cultured, Humans, Lymphocyte Activation, Mice, Inbred C57BL, Multiple Myeloma, Receptors, Immunologic, Mice, Knockout, CD8-Positive T-Lymphocytes, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
